#USA #San Francisco #Securities Fraud #stock decline #PROCEPT BioRobotics

PROCEPT BioRobotics Corporation: A Class Action Lawsuit Overview

PROCEPT BioRobotics Corporation, known for its innovative Aquablation therapy targeting enlarged prostate conditions, is currently facing a class action lawsuit that has raised concerns among investors. This legal action, led by Hagens Berman Sobol Shapiro LLP, points to significant undisclosed issues related to the company's inventory management that have culminated in a notable decline—approximately 18% in stock value—over the past few months.

The Allegations

The class action filed against PROCEPT cites that between February 28, 2024, and February 25, 2026, the company misled shareholders regarding its operational challenges and financial health, particularly in performance metrics for its single-use handpieces. These handpieces are an essential component of their flagship procedure, Aquablation. The lawsuit alleges that the company's communications were lacking transparency about the actual performance of its sales due to unreported excess inventory levels that were attributed to bulk purchasing discounts.

The complaint indicates that management's strategy involved pushing customers to place bulk orders—exceeding their immediate needs—by offering considerable financial incentives. This created an illusion of robust sales figures in the short term while eroding future sales potential. Such practices had the effect of artificially inflating revenues and success indicators that the company was publicly promoting.

Timeline of Events

The fallout began to unfold during a series of earnings disclosures throughout late 2025 and early 2026. The company's second-quarter 2025 results announced on August 6 revealed a startling drop in handpiece sales, far below analyst projections. This news triggered a sharp decline in the stock price and began to raise red flags among keen investors. Further, during the Q3 results later that year, PROCEPT management drastically reduced annual sales targets, revealing that they had not effectively managed customer-related inventories.

On February 25, 2026, the quarterly results disclosure shocked shareholders when PROCEPT finally admitted to a substantial inventory surplus, noting that over 10,000 excess handpieces existed relative to actual procedures performed. This led to a sequenced drop in their stock price of over 48% from its peak values.

Moving Forward

Investors who acquired shares within the class period and experienced substantial losses from the stock decline are being encouraged to contact Hagens Berman for representation in this lawsuit. The investigation aims to determine if PROCEPT intentionally obscured information regarding the sales practices relating to their handpieces.

Reed Kathrein, an attorney from Hagens Berman, stated, "Our focus is on the possibility that PROCEPT may have manipulated sales strategies to overstate perceived growth, impacting investor confidence and leading to significant financial losses for many."

If you believe you were misled by PROCEPT’s communication or have relevant information to assist the investigation, reaching out promptly is essential. Whistleblowers with non-public knowledge could also benefit from the SEC’s Whistleblower initiative, which offers potential rewards for information leading to successful enforcement actions.

Conclusion

This developing situation at PROCEPT BioRobotics serves as an important reminder of the complexities and challenges investors may face in navigating the corporate landscape. With significant legal implications ahead, stakeholders are advised to stay informed and consider their options. Further details on participating in the class action or contributing to the investigation can be found through Hagens Berman’s dedicated resources.